World journal of clinical oncology最新文献

{"title":"Extracellular vesicles circular RNA: A new perspective and clinical application potential for mediating chemoresistance in colorectal cancer.","authors":"Shu-Zhen Liu, Yan Liu, Chao-Li Wang, Yu-Jiao Li, Xiao-Qian Shan, Wei-Li Gao, Mei-Heng He, Lan Zhao","doi":"10.5306/wjco.v16.i7.107633","DOIUrl":"10.5306/wjco.v16.i7.107633","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a common and deadly malignancy worldwide, causing high morbidity and mortality rates. Chemoresistance continues to be the major barrier to the effective treatment of CRC. Circular RNA (circRNA), a recently identified class of non-coding RNA, has become an emerging focus in CRC research due to its abundant presence and stability in extracellular vesicles (EVs). The circRNA of EVs (EVs-circRNA) is closely associated with CRC progression and plays a pivotal role in chemoresistance mechanisms. This paper investigates the circRNA mechanism underlying different chemoresistance scenarios in CRC and explores the dual role of EVs-circRNA in mediating chemotherapy resistance. Furthermore, EVs-circRNA, a non-invasive biomarker for liquid biopsies, holds significant promise in clinical applications, ranging from early CRC diagnosis to monitoring disease progression and assessing prognosis. These studies provide a new perspective for uncovering CRC pathogenesis and lay the foundation for precision therapy and personalized treatment strategies for CRC. In the future, therapeutic strategies targeting EVs-circRNAs are anticipated to revolutionize CRC treatment, leading to improved therapeutic outcomes and enhanced quality of life for patients.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107633"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Closure techniques for esophageal reconstruction after total laryngectomy and their impact on fistula formation.","authors":"Adam Galazka, Katarzyna Stawarz, Karolina Bienkowska-Pluta, Monika Paszkowska, Magdalena Misiak-Galazka","doi":"10.5306/wjco.v16.i7.109246","DOIUrl":"10.5306/wjco.v16.i7.109246","url":null,"abstract":"<p><strong>Background: </strong>The rising incidence of laryngeal cancer has led to an increasing number of total laryngectomy procedures. While voice prostheses have significantly improved post-laryngectomy rehabilitation, the risk of salivary fistula remains a major complication. This study aims to compare the stapler and hand-sewn techniques for esophageal closure and evaluate their impact on fistula formation.</p><p><strong>Aim: </strong>To compare stapler-assisted and hand-sewn esophageal closure techniques after laryngectomy regarding their impact on salivary fistula formation.</p><p><strong>Methods: </strong>A total of 52 patients (44 men, 8 women), aged 43 to 77 years, underwent total laryngectomy. Esophageal reconstruction was performed using either a stapler (29 patients) or a hand-sewn technique (23 patients). A surgical stapler TA was used for esophageal closure in the stapler group. Patients were clinically monitored for fistula formation during the first 7 days postoperatively and again two weeks after discharge using fiberoptic examination.</p><p><strong>Results: </strong>A total of 22 salivary fistulas were recorded: 17 (77.3%) occurred following the hand-sewn technique, while 5 (22.7%) developed in the stapler group. Additionally, preoperative radiotherapy was identified as a statistically significant risk factor for fistula formation. No technical complications related to the stapler device were observed.</p><p><strong>Conclusion: </strong>Although hand-sewn closure is commonly used after total laryngectomy, stapler-assisted closure shows lower fistula rates and is a viable esophageal reconstruction alternative.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"109246"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Edge learning applications in the prediction and classification of combined hepatocellular-cholangiocarcinoma: A comprehensive narrative review.","authors":"Sami Akbulut, Cemil Colak","doi":"10.5306/wjco.v16.i7.107246","DOIUrl":"10.5306/wjco.v16.i7.107246","url":null,"abstract":"<p><p>Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare heterogeneous primary malignant liver tumor containing both hepatocellular and cholangiocarcinoma features. The complex presentation of cHCC-CCA tends to be poorly investigated, and the information derived from traditional diagnostic techniques (histopathology and radiological imaging) is often not optimal. Since cHCC-CCA is usually difficult to diagnose due to complex histopathological features (edge learning) as excessive photos, hence, achieves treatment delays and poor prognosis, the incorporation of advanced artificial intelligence like edge learning is able to improve the patient's outcome. Using artificial intelligence, particularly deep learning, has recently opened new doorways for the improvement of diagnostic accuracy. If artificial intelligence models are deployed on local devices, edge learning exercises this type of learning, which provides real time processing, improved data privacy and reduced bandwidth usage. This narrative review investigates the conceptual formulation of edge learning together with its opportunities for clinical applications in the prediction and classification of cHCC-CCA, the technical solution strategies, the clinical benefits it offers, and associated challenges and future directions.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107246"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lifestyle factors in hepatocellular carcinoma: From pathogenesis to prognosis.","authors":"He Zhao, Xiao-Wu Zhang, Xiao Li","doi":"10.5306/wjco.v16.i7.107723","DOIUrl":"10.5306/wjco.v16.i7.107723","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) represents a major global health burden, ranking third as the leading cause of cancer-related mortality worldwide. This comprehensive review examines the substantial body of evidence linking modifiable lifestyle factors to HCC pathogenesis and clinical outcomes. We systematically evaluate dietary components, alcohol consumption patterns, tobacco use, physical activity levels, and emerging factors including metabolic disorders, psychological stress, and sleep disturbances. These factors collectively influence hepatocarcinogenesis through diverse biological mechanisms, including genotoxic damage, metabolic dysregulation, chronic inflammatory responses, and gut microbiome-mediated pathways. The accumulated data underscore the urgent need to integrate lifestyle interventions into multidisciplinary HCC management.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107723"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the deficit: Assessing knowledge gaps in thyroid cancer management amongst physicians in the Democratic Republic of Congo.","authors":"John Bukasa-Kakamba, Ayrton I Bangolo, Nickson Poka, Christian Bompongo, Shruti Wadhwani, Nikita Wadhwani, Isis Kapinga Kalambayi, Manasse Bukasa Mutombo, Pierre Fwelo, Pascal Bayauli, Gael Menga, Andy Sifa, Cute Diazabakana, Guy Kingebeni, Mbuyi Mulumba, Djo Mambu, Richard Mfuke Bokondo, Jean-René M'Buyamba-Kabangu","doi":"10.5306/wjco.v16.i7.107495","DOIUrl":"10.5306/wjco.v16.i7.107495","url":null,"abstract":"<p><strong>Background: </strong>Thyroid cancer incidence is rising globally, including the Democratic Republic of Congo (DRC). Despite its increasing incidence, limited data exist on physicians' knowledge of thyroid cancer management in the DRC.</p><p><strong>Aim: </strong>To evaluate the knowledge levels of Congolese physicians regarding the diagnosis and treatment of thyroid nodules and cancers, and to identify existing gaps and areas for improvement.</p><p><strong>Methods: </strong>A descriptive cross-sectional study was conducted from June to August 2024, involving 369 physicians practicing in healthcare facilities across Kinshasa, DRC. Participants were selected using a multi-stage sampling method. Data were collected <i>via</i> a structured questionnaire covering thyroid cancer epidemiology, diagnostic methods, treatment approaches, and prognosis. Data were analyzed using SPSS version 25, employing descriptive and inferential statistics, with a <i>P</i> value ≤ 0.05 being considered as statistically significant.</p><p><strong>Results: </strong>Overall response rate was 96.1%. Of all participants, 68% were female and 32% were male physicians. General practitioners constituted 84.8% of respondents, with an average age of 34 years. While 53.7% demonstrated adequate knowledge of hypothyroidism management post-thyroidectomy and 61.2% identified the approach for hypoparathyroidism, only 5.1% recognized the need for radiotherapy in metastatic thyroid cancer cases. Awareness of anaplastic thyroid cancer treatment was limited (6.5%), and 90.2% of physicians were unfamiliar with the surgical complications. Moderate understanding was noted in diagnostic protocols, with 44.2% correctly identifying repeat fine-needle aspiration timing in Bethesda I cases. Knowledge of molecular genetics, recurrence risks, and metastasis patterns was remarkably low.</p><p><strong>Conclusion: </strong>This study highlights significant knowledge gaps among Congolese physicians regarding thyroid cancer management, especially about advanced treatment modalities and molecular genetics. Targeted educational programs and improved access to diagnostic tools are critical to bridging these deficits. Addressing these gaps can enhance the quality of thyroid cancer care and align clinical practices in the DRC with global standards.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"107495"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding horizons in esophageal squamous cell carcinoma: The promise of induction chemoimmunotherapy with radiotherapy.","authors":"Wenxue Ma, Natalia Baran","doi":"10.5306/wjco.v16.i7.104959","DOIUrl":"10.5306/wjco.v16.i7.104959","url":null,"abstract":"<p><p>Esophageal squamous cell carcinoma (ESCC) remains a highly aggressive malignancy with limited effective therapeutic options for patients with locally advanced unresectable disease. The study by Wei <i>et al</i>, featured in this issue, highlights the potential of induction chemoimmunotherapy followed by definitive radiotherapy or concurrent chemoradiotherapy to improve treatment outcomes in this challenging patient population. This retrospective analysis of 132 patients demonstrates promising results, including a median progression-free survival of 14.2 months and overall survival of 19.9 months, alongside an acceptable safety profile. Notably, the study identifies the effectiveness of induction therapy and maintenance immunotherapy as key prognostic factors, emphasizing the synergistic potential of integrating immune checkpoint inhibitors with radiotherapy. While these findings are encouraging, they require further validation through prospective trials, along with biomarker-based and immune response studies, to refine patient selection and maximize therapeutic benefits. This editorial explores the implications of this research, its impact on clinical practice, and future directions for advancing the treatment landscape of ESCC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"104959"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing neoadjuvant chemoradiation in resectable and borderline resectable pancreatic cancer: Evidence-based insights.","authors":"Gautam Sarma, Hima Bora, Partha P Medhi","doi":"10.5306/wjco.v16.i7.106107","DOIUrl":"10.5306/wjco.v16.i7.106107","url":null,"abstract":"<p><p>Since its inception, localized pancreatic cancer has been identified as a systemic illness. Hence, to increase its survival rates, surgical resection followed by adjuvant chemotherapy is used as a treatment option. A significant barrier, though, is the high morbidity and drawn-out recovery after extensive surgical resection, which may postpone or prohibit the prompt administration of adjuvant therapy. Thereby, acknowledging the efficacy of neoadjuvant therapy in various digestive tract malignancies like rectal, gastric, and oesophagal cancers in enhancing long-term survival and the likelihood of successful resection, researchers have turned their attention to exploring its potential benefits in the context of both resectable and borderline resectable pancreatic cancer (RPC). According to recent data, neoadjuvant chemoradiation has major advantages for both resectable and borderline RPC. These advantages include increased surgical resection rates, longer survival times, decreased recurrence rates, and better overall disease control with a manageable toxicity profile. Despite its benefits, research is still being done to determine the best way to sequence and combine chemotherapy and radiation. Furthermore, studies have demonstrated the potential for customized therapy regimens based on the patient's general health status and the tumor's biological behavior to maximize the neoadjuvant approach. As progress continues, neoadjuvant chemoradiation is set to become a key component of treatment for both resectable and borderline RPC, providing a more efficient way to manage this deadly condition. While further development is required to fully grasp its potential in enhancing long-term patient outcomes, evidence supports its increasing usage in clinical practice.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"106107"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental diagnosis of gallbladder carcinoma during or after routine cholecystectomy: A retrospective study with emphasis on clinicopathologic findings.","authors":"Kasturi Saikia, Zhengfan Xu, Nazila Azordegan, Beena Umar Ahsan","doi":"10.5306/wjco.v16.i7.104663","DOIUrl":"10.5306/wjco.v16.i7.104663","url":null,"abstract":"<p><strong>Background: </strong>Cholecystectomy is a common surgical procedure routinely performed for patients with benign gallbladder disease. The most common indications for cholecystectomy are acute or chronic cholecystitis with or without cholelithiasis. However, in rare instances, incidental findings ranging from benign to malignant conditions are encountered, of which gallbladder adenocarcinoma is an aggressive and fatal disease.</p><p><strong>Aim: </strong>To determine the prevalence of all incidental diagnoses in routinely performed cholecystectomy specimens, with a particular emphasis on adenocarcinoma, and to characterize the clinicopathological characteristics of malignant postoperative specimens.</p><p><strong>Methods: </strong>The electronic medical record and institutional pathology database were searched for analyses done on gallbladder specimens from patients who had a routine cholecystectomy for benign gallbladder disease during the study period (February 2000 to February 2023). A total of 30678 cholecystectomies performed across the study period were included for analysis. Patients who had preoperative findings or radiological results concerning malignancy were excluded. The demographic and clinical data including patient age and gender, preoperative diagnosis, radiographic results at time of diagnosis, gross and morphologic features of gallbladder specimens, and pathologic staging parameters according to the American Joint Committee on Cancer were recorded.</p><p><strong>Results: </strong>Of the 30678 cholecystectomy specimens received by the Department of Pathology from patients with who had cholecystectomy for putative benign gallbladder disease during the study period, 42 (0.14%) were determined to be incidental gallbladder adenocarcinoma and 1 was adenocarcinoma <i>in situ</i>. There were 2 benign incidental diagnoses, including 9 patients (0.02%) with accessory/ectopic liver lobe, and 3 with paraganglioma.</p><p><strong>Conclusion: </strong>Thorough histopathological examination of routine gallbladder specimens is important to provide an early diagnosis of unexpected gallbladder cancer to ensure that patients receive timely care when the disease is treatable.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"104663"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesentery morphological features on computed tomography for preoperative prediction of tumor invasion and lymph node metastasis in colon cancer.","authors":"Fei Wang, Chuan Huang, Hai-Qing Ma, Xue-Qing Yao, Jun-Jiang Wang, Jie Long","doi":"10.5306/wjco.v16.i7.108095","DOIUrl":"10.5306/wjco.v16.i7.108095","url":null,"abstract":"<p><strong>Background: </strong>Accurate identification of tumor invasion depth and lymph node (LN) involvement in patients with colon cancer (CC) is critical for guiding treatment strategies. However, the preoperative prediction of tumor invasion depth and LN metastasis in CC remains challenging. As the intestinal tumor develops, the fat density in the mesentery increases.</p><p><strong>Aim: </strong>To investigate the efficacy of computed tomography (CT) value change in the mesentery contributed by the tumor (CT-T value) for predicting tumor invasion depth and LN metastasis.</p><p><strong>Methods: </strong>Patients, who were diagnosed with CC and underwent surgery, were included and divided into the training and validation cohorts. CT-T values of the mesentery were extracted from the CT images. Cutoff points were determined using the receiver operating characteristic (ROC) curve, and the area under the ROC curve was employed to assess the performance of the CT-T value for tumor invasion depth and LN status prediction.</p><p><strong>Results: </strong>Cutoff values of 11.83 and 17.17 were identified to discriminate T1/2 <i>vs</i> T3/4 and N0 <i>vs</i> N1/2, respectively. With a cutoff CT-T value of 11.83, the total diagnostic accuracy for T stage was 83.1% (81.5% for the training cohort and 86.2% for the validation cohort). With a cutoff CT-T value of 17.17, the total diagnostic accuracy for N stage was 77.3% (75.8% for the training cohort and 80.1% for the validation cohort), which was higher than that of CT-reported LN metastasis.</p><p><strong>Conclusion: </strong>In this study, we explored an efficient method for predicting preoperative T and N stages using the tumor-contributed CT value of the mesentery in CC, which displayed superior predictive accuracy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"108095"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Untargeted metabolomics analysis of serum metabolic signatures as novel biomarkers for gastric carcinoma.","authors":"Le Ren, Jun Liu, Ya-Yun Xu, Zhen-Wang Shi","doi":"10.5306/wjco.v16.i7.108967","DOIUrl":"10.5306/wjco.v16.i7.108967","url":null,"abstract":"<p><strong>Background: </strong>In recent years, metabolomics has emerged as a novel platform for biomarker discovery. However, the metabolic profiles associated with gastric carcinoma (GC) remain insufficiently explored.</p><p><strong>Aim: </strong>To examine the differences in metabolites between patients with GC and healthy controls, with the objective of identifying potential serum biomarkers for GC diagnosis through a non-targeted metabolomics approach.</p><p><strong>Methods: </strong>An untargeted metabolic analysis was conducted on serum samples from 6 patients with GC and 6 healthy controls. Subsequently, the differential metabolites identified were further validated in serum samples from an expanded cohort of 50 patients with GC and 50 healthy controls. The discriminative capacity of differential metabolites in distinguishing patients with GC from healthy controls was assessed utilizing the receiver operating characteristic curve analysis. The association between the serum levels of differential metabolites and the disease severity, as determined by the tumor-node-metastasis staging system, was evaluated using Spearman's rank correlation coefficient.</p><p><strong>Results: </strong>Our findings revealed a significant alteration in the metabolic profile, characterized by 111 up-regulated and 55 down-regulated metabolites in patients with GC compared to healthy controls. Among the top 10 up-regulated metabolites, the serum concentrations of eight metabolites including fenpiclonil, methyclothiazide, 5-hydroxyindoleacetate, 3-pyridinecarboxylic acid, guanabenz, 2,2-dichloro-N-(3-chloro-1,4-dioxo-2-naphthyl) acetamide, epigallocatechin gallate, and dimethenamid, were further validated to be significantly elevated in a cohort of 50 patients diagnosed with GC compared to 50 healthy control subjects (<i>P</i> < 0.001). With the exception of 3-pyridinecarboxylic acid, the area under the curve values for the remaining seven metabolites exceeded 0.7, suggesting that these metabolites possess substantial diagnostic potential for distinguishing patients with GC from healthy individuals. Additionally, the serum concentrations of methyclothiazide (<i>r</i> = 0.615, <i>P</i> < 0.001), epigallocatechin gallate (<i>r</i> = 0.482, <i>P</i> = 0.004), and dimethenamid (<i>r</i> = 0.634, <i>P</i> < 0.001) demonstrated a significant positive correlation with the T stage in patients with GC. The serum concentrations of methyclothiazide (<i>r</i> = 0.438, <i>P</i> = 0.008) and epigallocatechin gallate (<i>r</i> = 0.383, <i>P</i> = 0.023) exhibited a significant positive correlation with the N stage in these patients.</p><p><strong>Conclusion: </strong>This study provides insights into the metabolic alterations associated with GC, and the identification of these biomarkers may enhance the clinical detection and management of the disease.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"108967"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}